S. Eppler

发表

Pharmacokinetics of a Slower Clearing Tissue Plasminogen Activator Variant, TNK-tPA, in Patients with Acute Myocardial Infarction

T. W. Love, E. Braunwald, C. Cannon, 1998, Thrombosis and Haemostasis.

Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration–effect relationship support clinical dose and regimen selection

H. Xiang, L. Damico-Beyer, S. Eppler, 2013, Cancer Chemotherapy and Pharmacology.

Evaluation of the Absolute Oral Bioavailability and Bioequivalence of Erlotinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in a Randomized, Crossover Study in Healthy Subjects

B. Lum, A. Rakhit, Jianfeng Lu, 2006, Journal of clinical pharmacology.

Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors

P. Hegde, K. Wong, L. Rosen, 2018, Cancer Chemotherapy and Pharmacology.

Determination of cobimetinib in human plasma using protein precipitation extraction and high-performance liquid chromatography coupled to mass spectrometry.

E. Choo, L. Musib, S. Eppler, 2014, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Absolute bioavailability and effect of formulation change, food, or elevated pH with rabeprazole on cobimetinib absorption in healthy subjects.

E. Choo, L. Musib, S. Eppler, 2013, Molecular pharmaceutics.

Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study

C. Redfern, M. Gordon, B. Lum, 2014, Cancer Chemotherapy and Pharmacology.

A population pharmacokinetic (PK) model for erlotinib (E), a small molecule inhibitor of the epidermal growth factor receptor (EGFR)

B. Lum, A. Rakhit, S. Eppler, 2005 .

Pharmacokinetics and pharmacodynamics of recombinant tissue‐type plasminogen activator following intravenous administration in rabbits: a comparison of three dosing regimens

T. Senn, N. Modi, S. Eppler, 1998, Biopharmaceutics & drug disposition.

Abstract 2774: Complete results from a phase Ia dose-escalation and dose-expansion study of single-agent MetMAb, a monovalent antagonist antibody to the receptor MET, administered intravenously in patients with locally advanced or metastatic solid tumors

P. Hegde, M. Ratain, R. Salgia, 2010 .

Evaluation of Cytochrome P450 3A4-Mediated Drug–Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation

Yuan Chen, L. Musib, S. Eppler, 2016, Clinical Pharmacokinetics.

Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach.

P. Kuebler, A. Joshi, T. Lu, 2013, Investigative ophthalmology & visual science.

Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins

J. Lofgren, P. Berman, V. Chisholm, 1999, Nature Biotechnology.

Clinical pharmacokinetics of bevacizumab in patients with solid tumors

Rene Bruno, W. Novotny, Bert Lum, 2008, Cancer Chemotherapy and Pharmacology.

Developmental immunotoxicology assessment of rituximab in cynomolgus monkeys.

G. Weinbauer, J. Beyer, S. Eppler, 2011, Toxicological sciences : an official journal of the Society of Toxicology.

P h a rmacokinetics of a Slower Clearing Tissue Plasminogen Activator Variant , TNK-tPA , in Patients with Acute Myocard i a l

E. Braunwald, C. Cannon, S. Eppler, 2018 .

Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure‐safety relationship in patients with non–small cell lung cancer

R. Bruno, B. Lum, A. Rakhit, 2006, Clinical pharmacology and therapeutics.

Lack of a pharmacokinetic interaction between trastuzumab and carboplatin in the presence of docetaxel: results from a phase Ib study in patients with HER2-positive metastatic or locally advanced inoperable solid tumors

C. Redfern, M. Gordon, B. Lum, 2015, Anti-cancer drugs.

A target‐mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans

Brian H Annex, T. Henry, S. Ellis, 2002, Clinical pharmacology and therapeutics.

Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease.

R. Hendel, R. Bonow, T. Henry, 2001, American heart journal.

Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma

R Bruno, S. Girish, O. Abidoye, 2017, Clinical pharmacology and therapeutics.

Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors

S. Hack, N. Choong, R. Bruno, 2015, Cancer Chemotherapy and Pharmacology.

Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies

P. Hegde, M. Ratain, R. Salgia, 2014, Clinical Cancer Research.

Abstract B75: A first in-human phase I study to evaluate the MEK1/2 inhibitor GDC-0623 in patients with advanced solid tumors.

A. El-Khoueiry, J. Bendell, I. Chang, 2013 .

Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors

John D. Davis, J. Bothos, I. Nijem, 2013, Journal of clinical pharmacology.

411 POSTER A phase I, open-label, dose-escalation study of the safety and pharmacology of MetMAb, a monovalent antagonist antibody to the receptor c-Met, administered IV in patients with locally advanced or metastatic solid tumors

M. Ratain, R. Salgia, M. Sovak, 2008 .

Determination of cobimetinib in human plasma using protein precipitation extraction and high-performance liquid chromatography coupled to mass spectrometry.

E. Choo, L. Musib, S. Eppler, 2014, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.